At OncoTech, we’re proud to unveil PeritonTreat – our pioneering immunotherapy solution that’s setting a new standard in cancer care.
PeritonTreat leverages the innovative compound DHMEQ, backed by extensive research and promising results from cellular and animal experiments conducted both in Japan and globally.
- Prostate Carcinoma
- Bladder Carcinoma
- Thyroid Carcinoma
- Breast Carcinoma
- Pancreatic Carcinoma
And our breakthroughs don’t end there.
PeritonTreat is also showing effectiveness in treating conditions previously challenging to manage, such as Adult T-cell Leukemia, Hodgkin Lymphoma, and even Glioblastoma.
Our mission to innovate extends into treatments for other serious conditions, including:
- Multiple Myeloma
- Crohn’s Disease Colitis
- Rheumatoid Arthritis
- Kidney Inflammation
- Diabetic Retinal Inflammation
Our mission to innovate extends into treatments for other serious conditions, including:
- Multiple Myeloma
- Crohn’s Disease Colitis
- Rheumatoid Arthritis
- Kidney Inflammation
- Diabetic Retinal Inflammation
With PeritonTreat, OncoTech reaffirms its commitment to progress. Our therapy is designed to be substantially more effective than current drug standards, offering new hope to patients worldwide.
The world’s first clinically tested and validated on-demand cancer and diabetes screening system powered by advanced AI.
An innovative anti-cancer immunotherapy based on DHMEQ and drug combinations for various cancer types.